BCL2L1 and Thrombocytopenia: The combination of low-dose BCL-XL and BCL-W inhibitors, such as navitoclax, with venetoclax may be effective and protects against cellular resistance to venetoclax without dose-limiting thrombocytopenia (NCT03181126) (25, 26).